Epilepsy, Partial Clinical Trial
Official title:
Meta-Analysis of VRX-RET-E22-303 and VRX-RET-E22-304: Two Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Studies of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extensions of Studies VRX-RET-E22-301 and VRX-RET-E22-302)
The objective of this meta-analysis is to provide data on long-term safety and efficacy following the recent positive Committee for Medicinal Products for Human Use (CHMP) opinion for retigabine using pooled data from ongoing open-label extension (OLE) Studies VRX-RET-E22-303 and VRX-RET-E22-304.
Data from the October 2009 data-cut of ongoing Studies VRX-RET-E22-303 (Study 303) and VRX-RET-E22-304 (Study 304) will be pooled, summarized, and published with the goal of providing updated long-term safety and efficacy information for subjects and prescribers following the recent positive CHMP opinion for retigabine for adjunctive use in patients with partial seizures. Studies 303 and 304 are the open-label extensions of two Phase 3 studies (VRX-RET-E22-301 and VRX-RET-E22-302), respectively. Studies 301 and 302 were randomized, double-blind, placebo-controlled, parallel-group, multicenter studies of 600 mg and 900 mg per day (Study 302) and 1200 mg per day (Study 301). All subjects who wished to enter the OLE studies and, in the opinion of the investigator, were expected to benefit from participation in the OLEs, entered a 6-week (Study 301) or 4-week (Study 302) transition phase in which their dose of retigabine was titrated to or maintained at 400 mg TID (Study 301) or 300 mg TID (Study 302). Upon completion of the Transition phase, subjects enrolled into the extension studies. Once enrolled in the OLE, doses could be adjusted within the range of 600 mg to 1200 mg per day. Treatment in Studies 303 and 304 is planned to continue until regulatory approval and commercialization of retigabine or until the program is discontinued. ;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00105040 -
A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
|
Phase 2 | |
| Completed |
NCT00160615 -
Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method
|
Phase 3 | |
| Completed |
NCT00175890 -
A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.
|
Phase 3 | |
| Completed |
NCT00152516 -
Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures
|
Phase 3 | |
| Completed |
NCT00113165 -
Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
|
Phase 3 | |
| Withdrawn |
NCT01691872 -
Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects
|
Phase 1 | |
| Completed |
NCT00160654 -
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
|
Phase 4 | |
| Terminated |
NCT01545518 -
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
|
Phase 2 | |
| Completed |
NCT00141414 -
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
|
Phase 2 | |
| Completed |
NCT01332539 -
An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy
|
N/A | |
| Completed |
NCT00355082 -
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
|
Phase 3 | |
| Completed |
NCT00152451 -
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
|
Phase 2 | |
| Withdrawn |
NCT02220972 -
To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures
|
Phase 4 | |
| Completed |
NCT00160628 -
Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy
|
Phase 3 | |
| Completed |
NCT00245713 -
Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy.
|
Phase 4 | |
| Terminated |
NCT01375374 -
Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide
|
Phase 3 | |
| Completed |
NCT00152373 -
Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS
|
Phase 3 | |
| Completed |
NCT00150709 -
A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
|
Phase 3 | |
| Completed |
NCT00643500 -
Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy
|
Phase 4 | |
| Completed |
NCT00152503 -
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
|
Phase 2 |